Trial Profile
A randomized, single-blind, parallel group, multiple oral dose study to evaluate the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren using market 300 mg tablet formulation in subjects with mild to moderate hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 05 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2009 Planned number of patients changed from 122 to 150 as reported by ClinicalTrials.gov.
- 08 Jul 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).